Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash

DSM will commence all-cash tender offer in May Tender Offer expected to be completed by June 30, 2012

Kensey Nash Corporation (Nasdaq: KNSY), today announced that it has entered into a definitive agreement with Royal DSM (DSM) (NYSE Euronext: DSM KON), under which DSM has agreed to acquire all of the common stock of Kensey Nash through a cash tender offer, followed by a merger with a subsidiary of DSM, for $38.50 per share in cash.

"We are very pleased to have entered into the merger agreement with DSM, as the transaction will deliver significant value to our stockholders.  The price to be paid to our stockholders represents a premium of 33% over our closing price on May 2, 2012," said Joe Kaufmann, President and Chief Executive Officer. 

Conceptus(R) Announces Settlement of Patent Infringement Lawsuit With Hologic

Hologic to Remove Adiana Permanent Contraception System From the Market

2012 Financial Guidance Updated

Conceptus, Inc. (CPTS), developer of the Essure^(R) procedure, the leading non-surgical permanent birth control method, today announced that it has reached an agreement with Hologic, Inc. (HOLX ) to settle the ongoing patent infringement litigation related to Hologic's Adiana Permanent Contraception System. The settlement agreement resolves all outstanding litigation between Conceptus and Hologic.

Align Technology Announces First Quarter Fiscal Year 2012 Results

• Q1 net revenues of $135.1 million increased 4.8% sequentially and 28.8% year-over-year
• Q1 Invisalign clear aligner revenue of $123.3 million increased 3.7% sequentially and 17.6% year-over-year with Invisalign case shipments of 85.3 thousand
• Q1 scanner and CAD/CAM services revenue of $11.8 million increased 17.8% sequentially
• Q1 GAAP diluted EPS was $0.26 and Q1 Non-GAAP diluted EPS was $0.27

Align Technology, Inc. (Nasdaq:ALGN ) today reported financial results for the first quarter of fiscal 2012 ended March 31, 2012.

Total net revenues for the first quarter of fiscal 2012 (Q1 12) were a $135.1 million. This is compared to $128.9 million reported in the fourth quarter of 2011 (Q4 11) and compared to $104.9 million reported in the first quarter of 2011 (Q1 11).

TSO3 resubmits documents to proceed with US regulatory clearance

TSO3 Inc. ("TSO3") (TSX: TOS.TO - News), an innovator in sterilization technology for medical devices in healthcare settings, announced today that it is resubmitting documentation to the United States (U.S.) regulatory authorities for the STERIZONE® 125L+ Sterilizer (3M™ Optreoz™ 125-Z) and associated accessories. This filing is aimed at obtaining clearance for the new generation sterilizer for commercialization in the United States .

"Resubmitting this updated filing has been a top priority for TSO3 over the past six weeks", commented R.M. (Ric) Rumble, CEO of TSO3. "Today's re-submittal is a follow-up to our original filing of June 30, 2011 , and provides the Agency with additional data addressing specific requests. We have had additional consultant input on this re-submittal and we are optimistic that this will lead to a positive outcome", added Mr. Rumble .